Drug profile · INN
bezlotoxumab
ZINPLAVA
bezlotoxumab (ZINPLAVA) is a toxin b inhibitor. Route of administration: injection. Current US regulatory status: approved.
FDA: approved EMA: approved Antiinfectives for systemic use (J06) J06BB21
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — bezlotoxumab
- US status
- approved
- Class
- Antiinfectives for systemic use (J06)
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
bezlotoxumab (ZINPLAVA) is a toxin b inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN bezlotoxumab
Brand ZINPLAVA
Mechanism Toxin B inhibitor
Target Toxin B
Therapeutic class Antiinfectives for systemic use (J06)
Route INJECTION
Formulation INJECTABLE
ATC code J06BB21
Mechanism of action
Toxin B inhibitor
Primary target: Toxin B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is bezlotoxumab?
bezlotoxumab (ZINPLAVA) is a toxin b inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for bezlotoxumab?
ZINPLAVA is a marketed brand name for bezlotoxumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bezlotoxumab?
bezlotoxumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.